DrugPatentWatch Database Preview

Astrazeneca Pharms Company Profile

ASTRAZENECA PHARMS has nineteen approved drugs.

There are sixty-four US patents protecting ASTRAZENECA PHARMS drugs.

There are one thousand two hundred and sixteen patent family members on ASTRAZENECA PHARMS drugs in sixty-seven countries and one hundred and twenty-nine supplementary protection certificates in seventeen countries.

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca Pharms	NEXIUM	esomeprazole magnesium	CAPSULE, DELAYED REL PELLETS;ORAL	021153-002	Feb 20, 2001	AB	RX	Yes	Yes	6,428,810*PED	Start Trial			Y	Start Trial
Astrazeneca Pharms	MOVANTIK	naloxegol oxalate	TABLET;ORAL	204760-002	Sep 16, 2014		RX	Yes	Yes	8,617,530	Start Trial				Start Trial
Astrazeneca Pharms	MOVANTIK	naloxegol oxalate	TABLET;ORAL	204760-002	Sep 16, 2014		RX	Yes	Yes	7,662,365	Start Trial	Y	Y		Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Astrazeneca Pharms	PULMICORT RESPULES	budesonide	SUSPENSION;INHALATION	020929-002	Aug 8, 2000	6,899,099*PED	Start Trial
Astrazeneca Pharms	PRILOSEC	omeprazole	CAPSULE, DELAYED REL PELLETS;ORAL	019810-001	Sep 14, 1989	6,147,103*PED	Start Trial
Astrazeneca Pharms	SEROQUEL	quetiapine fumarate	TABLET;ORAL	020639-006	Oct 4, 2005	4,879,288*PED	Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Tablets	25 mg	➤ Subscribe	2005-08-12
➤ Subscribe	Tablets	100 mg, 200 mg and 300 mg	➤ Subscribe	2006-02-21
➤ Subscribe	Delayed-release	20 mg and 40 mg	➤ Subscribe	2005-08-05
➤ Subscribe	For Injection	20 mg/vial and 40 mg/vial	➤ Subscribe	2009-11-23
➤ Subscribe	Inhalation Suspension	1 mg/2 mL	➤ Subscribe	2010-05-28
➤ Subscribe	Delayed-release Tablets	20 mg	➤ Subscribe	2012-03-30
➤ Subscribe	Tablets	60 mg	➤ Subscribe	2015-09-30
➤ Subscribe	Tablets	12.5 mg and 25 mg	➤ Subscribe	2018-09-17
➤ Subscribe	Tablets	50 mg, 150 mg and 400 mg	➤ Subscribe	2007-02-12
➤ Subscribe	Delayed-release for Oral Suspension	2.5 mg and 5 mg	➤ Subscribe	2018-09-24
➤ Subscribe	Inhalation Suspension	0.25 mg/2 mL and 0.5 mg/2 mL	➤ Subscribe	2005-09-15
➤ Subscribe	Delayed-release Capsules	20 mg	➤ Subscribe	2007-03-19
➤ Subscribe	Tablets	90 mg	➤ Subscribe	2015-07-20
➤ Subscribe	Tablets	500 mcg	➤ Subscribe	2015-03-02

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2673237	2019C/519	Belgium	Start Trial	PRODUCT NAME: LOKELMA - CYCLOSILICATE DE ZIRCONIUM SODIQUE; AUTHORISATION NUMBER AND DATE: EU/1/17/1173 20180326
0268956	SPC/GB98/040	United Kingdom	Start Trial	PRODUCT NAME: RABEPRAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE SODIUM SALT; REGISTERED: UK 10555/0010 19980508; UK 10555/0008 19980508
1758590	2017C/063	Belgium	Start Trial	PRODUCT NAME: SEL DE SODIUM D'ACIDE DESOXYCHOLIQUE; AUTHORISATION NUMBER AND DATE: SE/H/1547/01/DC 20170612
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.